Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Laboratorios Silanes S.A. de C.V. clinical trials
The registry lists 55 studies whose lead sponsor is Laboratorios Silanes S.A. de C.V. or one of 1 company grouped under it. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the Laboratorios Silanes S.A. de C.V. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Laboratorios Silanes S.A. de C.V..
- Laboratorios Silanes S.A. de C.V.44 studiesSame company
Something wrong?
- Instituto Bioclon S.A. de C.V.11 studies →Subsidiary
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 50 of 55. Browse all 55 →
- Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout ArthritisRecruitingNCT06863701Phase 3
- Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus LoratadineCompletedNCT06531707Phase 3
- Efficacy and Safety of Celecoxib/Acetaminophen Versus Celecoxib for Diagnosed Osteoarthritis in Acute ExacerbationCompletedNCT06863636Phase 3
- Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus DesloratadineCompletedNCT06916884Phase 3
- Comparative Bioavailability Study Between Etoricoxib / Betamethasone Administered Individually or in CombinationCompletedNCT07454369Phase 1
- Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination.CompletedNCT07444164Phase 1
- Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle SpasmCompletedNCT06863662Phase 3
- Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and SynovitisCompletedNCT07328022Phase 3
- Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment FailureCompletedNCT04841096Phase 3
- Efficacy and Safety in the Combination of Celecoxib / Pregabalin / Vitamin B for Low Back Chronic PainCompletedNCT06516094Phase 3
- Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial HypertensionCompletedNCT04927299Phase 3
- Efficacy and Safety of Etoricoxib/Cyanocobalamin Versus Etoricoxib for Acute Low Back PainCompletedNCT06517823Phase 3
- Efficacy and Safety of Dexketoprofen/Vitamin B Vs Dexketoprofen for Post-traumatic Cervical Sprain Grade I-IICompletedNCT05001555Phase 3
- Non-interaction Study Between Pregabalin and Tramadol, Administered Individually or Combination, in Healthy SubjectsCompletedNCT05389150Phase 1
- Efficacy and Safety of Pregabalin/Tramadol Combination Versus Pregabalin in Acute Pain of Neuropathic OriginCompletedNCT05324059Phase 3
- Comparative Bioavailability Study Between Etoricoxib and Tramadol, Administered Individually or in CombinationCompletedNCT05533073Phase 1
- Pharmacokinetic Interaction Between Ibuprofen and Acetaminophen, Tablets Administered Individually or in CombinationCompletedNCT05428306Phase 1
- Pharmacokinetic Interaction Between Ibuprofen and Acetaminophen Oral SuspensionCompletedNCT05428293Phase 1
- Efficacy and Safety of Fixed-dose Combination of Etoricoxib/Tramadol vs Acetaminophen/Tramadol for Acute Low Back PainCompletedNCT04968158Phase 3
- Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of ScalpCompletedNCT05105139
- Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With DyslipidaemiaCompletedNCT04862962
- Pharmacokinetic Study Protocol of ANAWIDOW Lyophilized Powder for Solution for Intravenous Use in Fasting ConditionsCompletedNCT04848714Phase 1
- Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP.Status unknownNCT04882293Phase 3
- Non-interaction Study of Chlorthalidone and Losartan in Fixed Combination, in Healthy Subjects, Under Fasting ConditionsCompletedNCT05090449Phase 1
- Comparison of Bioavailability of Dexketoprofen-Vit B vs Dexketoprofen, in Healthy Subjects, Under Fasting ConditionsCompletedNCT05027126Phase 1
- Study of no Pharmacokinetic Interaction Between Rosuvastatin 20mg and Ezetimibe10mg, Fixed Dose vs Individual ComponentsCompletedNCT04895059Phase 1
- Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 DiabetesSuspendedNCT04943692Phase 3
- Safety of doTBal® in Patients With Tuberculosis: Conduction of an Intensive Pharmacovigilance ProgramCompletedNCT04916899
- BIOAVAILABILITY OF Glimepiride/Extended Release Metformin (GLI/METXR): High Fat Diet StudyCompletedNCT01437813Phase 1
- BIOAVAILABILITY OF GLI/METXR (4/850 mg)CompletedNCT01437800Phase 1
- Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2WithdrawnNCT04626089Phase 2
- Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.CompletedNCT04625985Phase 2
- A Trial of Equine F (ab')2 Antivenom for Treatment of Scorpion Envenomation in MoroccoCompletedNCT01336660Phase 2/3
Sponsor listed in the registry: Instituto Bioclon S.A. de C.V.
- Black Widow Spider Antivenin for Patients With Systemic LatrodectismCompletedNCT00657540Phase 3
Sponsor listed in the registry: Instituto Bioclon S.A. de C.V.
- Gastric Tolerability and Pharmacokinetics of DMMET-01CompletedNCT00960882Phase 1
- Tolerability and Pharmacokinetics of Metformin and Metformin Extended Release (ER)CompletedNCT00941239Phase 1
- Efficacy Study of Metformin Glycinate on Postprandial LipemiaStatus unknownNCT02064881Phase 2/3
- Clinical Trial to Evaluate Safety and pK Profile of Metformin Glycinate in Healthy VolunteersCompletedNCT01560481Phase 1
- Metformin Glycinate on Metabolic Control and Inflammatory Mediators in Type 2 DiabetesCompletedNCT01386671Phase 3
- Fixed Dose Combination of Fluoxetin and Metformin in the Management of Overweight and ObesitySuspendedNCT03051451Phase 2
- Study to Evaluate the Efficacy of Two Treatment Schemes With Antivipmyn ® for the Treatment of Snake Bite EnvenomationTerminatedNCT00639951Phase 4
Sponsor listed in the registry: Instituto Bioclon S.A. de C.V.
- A Comparison of Crotalinae Equine Immune F(ab)2 Antivenom (Anavip) and Crotalidae Polyvalent Immune Fab,CompletedNCT00868309Phase 2
Sponsor listed in the registry: Instituto Bioclon S.A. de C.V.
- Open Label Clinical Trial of Anascorp® in Pediatric Patients With Scorpion Sting EnvenomationCompletedNCT01599936Phase 3
Sponsor listed in the registry: Instituto Bioclon S.A. de C.V.
- The Efficacy and Safety of Aracmyn in Patients With Systemic LatrodectismCompletedNCT00247078Phase 2
Sponsor listed in the registry: Instituto Bioclon S.A. de C.V.
- Metformin vs Conjugated Linoleic Acid and an Intervention Program With Healthy Habits in Obese ChildrenStatus unknownNCT02063802Phase 2
- Open Label Study of Alacramyn® in Pediatric Patients With Scorpion Sting EnvenomationCompletedNCT01599923Phase 3
Sponsor listed in the registry: Instituto Bioclon S.A. de C.V.
- Phase 3 Multicenter Comparative Study to Confirm Safety and Effectiveness of the F(ab)2 Antivenom Anavip.CompletedNCT00636116Phase 3
Sponsor listed in the registry: Instituto Bioclon S.A. de C.V.
- Endothelial Disfunction Treatment With Glimepiride/Metformin Combination (Glimetal) in Type 2 Diabetes PatientsCompletedNCT01429818Phase 4
- Double-Blind, Alacramyn® vs. Placebo in Pediatric PatientsCompletedNCT00685230Phase 2/3
Sponsor listed in the registry: Instituto Bioclon S.A. de C.V.
- Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting EnvenomationCompletedNCT00624078Phase 2/3
Sponsor listed in the registry: Instituto Bioclon S.A. de C.V.